Page last updated: 2024-11-02

pioglitazone and Carcinoma, Transitional Cell

pioglitazone has been researched along with Carcinoma, Transitional Cell in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, R1
Metcalfe, MJ1
Ferguson, JE1
Mokkapati, S1
Nogueras González, GM1
Dinney, CP1
Navai, N1
McConkey, DJ1
Sahai, SK1
Kamat, AM1

Other Studies

1 other study available for pioglitazone and Carcinoma, Transitional Cell

ArticleYear
Effects of thiazolidinedione in patients with active bladder cancer.
    BJU international, 2018, Volume: 121, Issue:2

    Topics: Aged; Carcinoma, Transitional Cell; Cystectomy; Diabetes Mellitus; Disease-Free Survival; Female; Hu

2018